Vitamin D-3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?

Linda Rolf; Anne-Hilde Muris; Ruud Theunissen; Raymond Hupperts; Jan Damoiseaux; Joost Smolders

doi:10.1016/j.jneuroim.2017.11.007

Vitamin D-3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?

Linda Rolf, Anne-Hilde Muris, Ruud Theunissen, Raymond Hupperts, Jan Damoiseaux, Joost Smolders^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Web of Science)

Abstract

Vitamin D-3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4(+) T cells in vitro. We investigated effects of 48-weeks vitamin D-3 supplements on CD25-expression by CD4(+) T cells of patients with multiple sclerosis (MS). There was no significant difference between the vitamin D-3 (n = 30) and placebo group (n = 23) in IL2RA mRNA-expression by PBMC. Likewise, CD25 cell surface-expression by conventional or regulatory T cells (Treg) did not differ between groups, although Treg CD25-expression and circulating soluble-CD25 levels decreased significantly in the placebo but not vitamin D-3-group. We speculate that vitamin D-3 may promote the maintenance of CD25-related immune homeostasis in MS.

Original language	English
Pages (from-to)	50-57
Number of pages	8
Journal	Journal of Neuroimmunology
Volume	314
DOIs	https://doi.org/10.1016/j.jneuroim.2017.11.007
Publication status	Published - 15 Jan 2018

Keywords

CD25
IL-2 receptor
Multiple sclerosis
Regulatory T cell
T cell
Vitamin D
REGULATORY T-CELLS
INTERLEUKIN-2 RECEPTOR LEVELS
RANDOMIZED CONTROLLED-TRIAL
SOLUBLE INTERLEUKIN-2-RECEPTOR
DOSE CHOLECALCIFEROL
INTERFERON BETA-1A
IMMUNE-RESPONSES
FOXP3 EXPRESSION
IL-2
PROLIFERATION

Access to Document

10.1016/j.jneuroim.2017.11.007

Cite this

@article{58be62c9530547439ac8a7c347aff21c,

title = "Vitamin D-3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?",

abstract = "Vitamin D-3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4(+) T cells in vitro. We investigated effects of 48-weeks vitamin D-3 supplements on CD25-expression by CD4(+) T cells of patients with multiple sclerosis (MS). There was no significant difference between the vitamin D-3 (n = 30) and placebo group (n = 23) in IL2RA mRNA-expression by PBMC. Likewise, CD25 cell surface-expression by conventional or regulatory T cells (Treg) did not differ between groups, although Treg CD25-expression and circulating soluble-CD25 levels decreased significantly in the placebo but not vitamin D-3-group. We speculate that vitamin D-3 may promote the maintenance of CD25-related immune homeostasis in MS.",

keywords = "CD25, IL-2 receptor, Multiple sclerosis, Regulatory T cell, T cell, Vitamin D, REGULATORY T-CELLS, INTERLEUKIN-2 RECEPTOR LEVELS, RANDOMIZED CONTROLLED-TRIAL, SOLUBLE INTERLEUKIN-2-RECEPTOR, DOSE CHOLECALCIFEROL, INTERFERON BETA-1A, IMMUNE-RESPONSES, FOXP3 EXPRESSION, IL-2, PROLIFERATION",

author = "Linda Rolf and Anne-Hilde Muris and Ruud Theunissen and Raymond Hupperts and Jan Damoiseaux and Joost Smolders",

year = "2018",

month = jan,

day = "15",

doi = "10.1016/j.jneuroim.2017.11.007",

language = "English",

volume = "314",

pages = "50--57",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - Vitamin D-3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis

T2 - Attenuation of progressive disturbances?

AU - Rolf, Linda

AU - Muris, Anne-Hilde

AU - Theunissen, Ruud

AU - Hupperts, Raymond

AU - Damoiseaux, Jan

AU - Smolders, Joost

PY - 2018/1/15

Y1 - 2018/1/15

N2 - Vitamin D-3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4(+) T cells in vitro. We investigated effects of 48-weeks vitamin D-3 supplements on CD25-expression by CD4(+) T cells of patients with multiple sclerosis (MS). There was no significant difference between the vitamin D-3 (n = 30) and placebo group (n = 23) in IL2RA mRNA-expression by PBMC. Likewise, CD25 cell surface-expression by conventional or regulatory T cells (Treg) did not differ between groups, although Treg CD25-expression and circulating soluble-CD25 levels decreased significantly in the placebo but not vitamin D-3-group. We speculate that vitamin D-3 may promote the maintenance of CD25-related immune homeostasis in MS.

AB - Vitamin D-3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4(+) T cells in vitro. We investigated effects of 48-weeks vitamin D-3 supplements on CD25-expression by CD4(+) T cells of patients with multiple sclerosis (MS). There was no significant difference between the vitamin D-3 (n = 30) and placebo group (n = 23) in IL2RA mRNA-expression by PBMC. Likewise, CD25 cell surface-expression by conventional or regulatory T cells (Treg) did not differ between groups, although Treg CD25-expression and circulating soluble-CD25 levels decreased significantly in the placebo but not vitamin D-3-group. We speculate that vitamin D-3 may promote the maintenance of CD25-related immune homeostasis in MS.

KW - CD25

KW - IL-2 receptor

KW - Multiple sclerosis

KW - Regulatory T cell

KW - T cell

KW - Vitamin D

KW - REGULATORY T-CELLS

KW - INTERLEUKIN-2 RECEPTOR LEVELS

KW - RANDOMIZED CONTROLLED-TRIAL

KW - SOLUBLE INTERLEUKIN-2-RECEPTOR

KW - DOSE CHOLECALCIFEROL

KW - INTERFERON BETA-1A

KW - IMMUNE-RESPONSES

KW - FOXP3 EXPRESSION

KW - IL-2

KW - PROLIFERATION

U2 - 10.1016/j.jneuroim.2017.11.007

DO - 10.1016/j.jneuroim.2017.11.007

M3 - Article

C2 - 29153546

SN - 0165-5728

VL - 314

SP - 50

EP - 57

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

ER -